Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alprazolam + escitalopram is a combination of two pharmaceutical drugs used primarily in the management of anxiety and depressive disorders. Alprazolam is a benzodiazepine that acts as a central nervous system depressant by enhancing the effect of gamma-aminobutyric acid (GABA), leading to sedative, anxiolytic, and muscle relaxant properties. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels in the brain by inhibiting its reabsorption, thereby improving mood and reducing symptoms of depression and anxiety. While both medications can be effective for their respective indications, their concurrent use can lead to additive effects on sedation, cognitive impairment, and other central nervous system side effects. This combination should only be used under careful medical supervision due to potential risks such as over-sedation, increased risk of falls (especially in elderly patients), cognitive impairment, dependence (primarily from alprazolam), and exacerbation of overlapping side effects[1][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alprazolam + escitalopram.